Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines

ObjectivesMedulloblastoma (MB) is treated with surgery and chemotherapy, with or without irradiation, but unfortunately >20% of the patients are not cured, and treatment comes with serious long-term side effects, so novel treatments are urgently needed. Phosphoinositide 3-kinases (PI3K), fibr...

Full description

Bibliographic Details
Main Authors: Monika Lukoseviciute, Henrietta Maier, Eleni Poulou-Sidiropoulou, Erika Rosendahl, Stefan Holzhauser, Tina Dalianis, Ourania N. Kostopoulou
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.748657/full
id doaj-8a7914929737482287a7f7ecd227847a
record_format Article
spelling doaj-8a7914929737482287a7f7ecd227847a2021-09-24T06:14:01ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.748657748657Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell LinesMonika LukoseviciuteHenrietta MaierEleni Poulou-SidiropoulouErika RosendahlStefan HolzhauserTina DalianisOurania N. KostopoulouObjectivesMedulloblastoma (MB) is treated with surgery and chemotherapy, with or without irradiation, but unfortunately >20% of the patients are not cured, and treatment comes with serious long-term side effects, so novel treatments are urgently needed. Phosphoinositide 3-kinases (PI3K), fibroblast growth factor receptors (FGFR), and cyclin-D kinases (CDK) play critical roles in cancer, and especially PI3K is crucial in MB, so here targeted therapies against them were explored.MethodsMB cell lines DAOY and UW228-3 were exposed to PI3K (BYL719), FGFR (JNJ-42756493), and CDK4/6 (PD-0332991) inhibitors, as single or combined treatments, and their viability, cell confluence, apoptosis, and cytotoxicity were examined. Moreover, the inhibitors were combined with cisplatin, vincristine, or irradiation.ResultsSingle treatments with FGFR, PI3K, or CDK4/6 inhibitors decreased viability and proliferation slightly; however, when combining two inhibitors, or the inhibitors with irradiation, sensitivity was enhanced and lower doses could be used. A more complex pattern was obtained when combining the inhibitors with cisplatin and vincristine.ConclusionsThe data suggest that combination treatments with PI3K, FGFR, and CDK4/6 inhibitors for MB could be beneficial and their use should be pursued further. Likewise, their combination with irradiation gave positive effects, while the addition of cisplatin and vincristine resulted in more complex patterns, which need to be investigated further.https://www.frontiersin.org/articles/10.3389/fonc.2021.748657/fullchildhood cancermedulloblastoma (MB)targeted therapyPI3K inhibitorsFGFR inhibitorsCDK4/6 inhibitors
collection DOAJ
language English
format Article
sources DOAJ
author Monika Lukoseviciute
Henrietta Maier
Eleni Poulou-Sidiropoulou
Erika Rosendahl
Stefan Holzhauser
Tina Dalianis
Ourania N. Kostopoulou
spellingShingle Monika Lukoseviciute
Henrietta Maier
Eleni Poulou-Sidiropoulou
Erika Rosendahl
Stefan Holzhauser
Tina Dalianis
Ourania N. Kostopoulou
Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
Frontiers in Oncology
childhood cancer
medulloblastoma (MB)
targeted therapy
PI3K inhibitors
FGFR inhibitors
CDK4/6 inhibitors
author_facet Monika Lukoseviciute
Henrietta Maier
Eleni Poulou-Sidiropoulou
Erika Rosendahl
Stefan Holzhauser
Tina Dalianis
Ourania N. Kostopoulou
author_sort Monika Lukoseviciute
title Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
title_short Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
title_full Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
title_fullStr Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
title_full_unstemmed Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
title_sort targeting pi3k, fgfr, cdk4/6 signaling pathways together with cytostatics and radiotherapy in two medulloblastoma cell lines
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-09-01
description ObjectivesMedulloblastoma (MB) is treated with surgery and chemotherapy, with or without irradiation, but unfortunately >20% of the patients are not cured, and treatment comes with serious long-term side effects, so novel treatments are urgently needed. Phosphoinositide 3-kinases (PI3K), fibroblast growth factor receptors (FGFR), and cyclin-D kinases (CDK) play critical roles in cancer, and especially PI3K is crucial in MB, so here targeted therapies against them were explored.MethodsMB cell lines DAOY and UW228-3 were exposed to PI3K (BYL719), FGFR (JNJ-42756493), and CDK4/6 (PD-0332991) inhibitors, as single or combined treatments, and their viability, cell confluence, apoptosis, and cytotoxicity were examined. Moreover, the inhibitors were combined with cisplatin, vincristine, or irradiation.ResultsSingle treatments with FGFR, PI3K, or CDK4/6 inhibitors decreased viability and proliferation slightly; however, when combining two inhibitors, or the inhibitors with irradiation, sensitivity was enhanced and lower doses could be used. A more complex pattern was obtained when combining the inhibitors with cisplatin and vincristine.ConclusionsThe data suggest that combination treatments with PI3K, FGFR, and CDK4/6 inhibitors for MB could be beneficial and their use should be pursued further. Likewise, their combination with irradiation gave positive effects, while the addition of cisplatin and vincristine resulted in more complex patterns, which need to be investigated further.
topic childhood cancer
medulloblastoma (MB)
targeted therapy
PI3K inhibitors
FGFR inhibitors
CDK4/6 inhibitors
url https://www.frontiersin.org/articles/10.3389/fonc.2021.748657/full
work_keys_str_mv AT monikalukoseviciute targetingpi3kfgfrcdk46signalingpathwaystogetherwithcytostaticsandradiotherapyintwomedulloblastomacelllines
AT henriettamaier targetingpi3kfgfrcdk46signalingpathwaystogetherwithcytostaticsandradiotherapyintwomedulloblastomacelllines
AT elenipoulousidiropoulou targetingpi3kfgfrcdk46signalingpathwaystogetherwithcytostaticsandradiotherapyintwomedulloblastomacelllines
AT erikarosendahl targetingpi3kfgfrcdk46signalingpathwaystogetherwithcytostaticsandradiotherapyintwomedulloblastomacelllines
AT stefanholzhauser targetingpi3kfgfrcdk46signalingpathwaystogetherwithcytostaticsandradiotherapyintwomedulloblastomacelllines
AT tinadalianis targetingpi3kfgfrcdk46signalingpathwaystogetherwithcytostaticsandradiotherapyintwomedulloblastomacelllines
AT ouraniankostopoulou targetingpi3kfgfrcdk46signalingpathwaystogetherwithcytostaticsandradiotherapyintwomedulloblastomacelllines
_version_ 1717370119465730048